This move is a reversal from the day prior, which saw price move down.The post Novo Nordisk A S (NVO): Price Now Near $67.6; Daily Chart Shows Downtrend on 20 Day Basis appeared...
Novo Nordisk (NYSE:NVO) had declared $0.683/share interim dividend.Payable April 7; for shareholders of record March 29; ex-div March 26.See NVO Dividend Scorecard, Yield Chart,...
The WisdomTree Global exU.S. Quality Dividend Growth ETF (DNL) was launched on 06/16/2006, and is a smart beta exchange traded fund designed to offer broad exposure to the World...
Launched on 05/07/2014, the WisdomTree International Hedged Quality Dividend Growth ETF (IHDG) is a smart beta exchange traded fund offering broad exposure to the Broad Developed...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Sell | Sell | Buy | Buy |
| Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Buy | Strong Buy |
| Summary | Strong Sell | Strong Sell | Strong Sell | Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 18.00 | 97.92 | 12.15 | -69.68 | -79.47% | 23.32M | NASDAQ | |||
| 244.01 | 244.91 | 236.65 | +20.70 | +9.27% | 57.28M | NYSE | |||
| 16.65 | 17.27 | 16.50 | -0.69 | -3.98% | 3.14M | NYSE | |||
| 1.09 | 1.14 | 1.03 | -0.0700 | -6.03% | 20.20M | NYSE | |||
| 7.23 | 7.37 | 7.20 | -0.18 | -2.43% | 9.40M | NYSE | |||
| 141.09 | 163.90 | 135.01 | -17.27 | -10.91% | 16.64M | NYSE | |||
| 76.22 | 76.60 | 75.98 | -0.09 | -0.12% | 9.51M | NYSE | |||
| 3.71 | 4.00 | 3.66 | -0.31 | -7.71% | 342.55K | NASDAQ | |||
| 13.14 | 18.68 | 12.05 | -5.53 | -29.62% | 60.20M | NASDAQ | |||
| 17.19 | 18.21 | 17.10 | -2.57 | -13.01% | 27.18M | NASDAQ | |||
| 26.77 | 28.93 | 26.46 | -2.51 | -8.57% | 15.35M | NYSE | |||
| 0.00007 | 0.00 | 0.00 | 0.00000 | 0.00% | 0.00K | OTC Markets | |||
| 8.62 | 9.49 | 8.51 | -0.80 | -8.49% | 50.42M | NYSE | |||
| 2.22 | 2.25 | 2.19 | -0.01 | -0.45% | 609.86K | NASDAQ | |||
| 23.34 | 24.55 | 22.73 | -0.70 | -2.91% | 68.09M | NYSE |
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.